1. Home
  2. HQ vs PRTC Comparison

HQ vs PRTC Comparison

Compare HQ & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HQ

Horizon Quantum Holdings Ltd. Class A Ordinary Shares

N/A

Current Price

$12.22

Market Cap

499.5M

Sector

N/A

ML Signal

N/A

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$17.61

Market Cap

400.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HQ
PRTC
Founded
2018
2015
Country
Singapore
United States
Employees
44
90
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
499.5M
400.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HQ
PRTC
Price
$12.22
$17.61
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
229.2K
13.6K
Earning Date
05-05-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.09
Revenue Growth
N/A
N/A
52 Week Low
$8.29
$14.50
52 Week High
$14.22
$19.92

Technical Indicators

Market Signals
Indicator
HQ
PRTC
Relative Strength Index (RSI) 56.65 54.15
Support Level $9.08 $16.67
Resistance Level $12.70 $18.70
Average True Range (ATR) 1.11 0.75
MACD 0.17 -0.04
Stochastic Oscillator 80.29 37.09

Price Performance

Historical Comparison
HQ
PRTC

About HQ Horizon Quantum Holdings Ltd. Class A Ordinary Shares

Horizon Quantum Holdings Ltd is building software infrastructure to make quantum computers accessible to commercial enterprises and hardware providers. By bridging the gap between hardware and applications, the company seeks to equip developers, researchers, and enterprises with the quantum software infrastructure needed to solve real-world problems. The company is developing tools that can automatically accelerate code written for conventional computers on quantum computers.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: